Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer...

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed...

(EU), for second line treatment of metastatic melanoma in November 2012. Nivolumab, in combination with ipilimumab is indicated for the treatment of intermediate...

molecules, and the first clinical trial was launched in 2006, evaluating nivolumab. As of 2017, more than 500 clinical trials involving PD-1 and PD-L1 inhibitors...

the combination of CIMAvax with the PD-1 inhibitor checkpoint inhibitor nivolumab was safe and well tolerated in 13 people with advanced non-small cell...

Approved checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab. Dendritic cell therapy provokes anti-tumor responses...

designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. Relatlimab is a Lymphocyte activation gene-3 (LAG-3)...

the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a...

the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have...

evaluated whether Nivolumab can be used for the treatment of a Hodgkin's lymphoma. The evidence is very uncertain about the effect of Nivolumab for patients...

combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma. Sitravatinib is being evaluated in ongoing trials...

antibody nivolumab (under the brand name Opdivo and developed by Bristol-Myers Squibb) were published in 2010. It was approved in 2014. Nivolumab is approved...

Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab...

survival benefits.[citation needed] In August 2018, the FDA approved nivolumab to treat patients with metastatic small cell lung cancer (SCLC) who failed...

that do not. Treatment with pembrolizumab, atezolizumab, or combination nivolumab plus ipilimumab are all superior to chemotherapy alone against tumors...

system to fight cancer. Nivolumab is a fully human IgG4 antibody targeting programmed death receptor 1 (PD-1). In 2015, nivolumab was approved for the treatment...

recently reviewed. The evidence is very uncertain about the effect of Nivolumab for patients with a Hodgkin's lymphoma e.g. on the overall survival. Increased...

inhibitors (e.g. sunitinib), checkpoint inhibitors (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab) Contrast agent Gadolininum based contrast...

CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy". Investigational New...

(NCT05678673) is a phase 3, randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell...

activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab Mouse Afelimomab...

earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto...

a combination therapy with both anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) in October 2015. The molecular factors and receptors necessary making...

[citation needed] In October 2020, the FDA approved the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults...

(BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research...

include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor...

for treatment of metastatic melanoma. In 2014, the U.S. FDA approved nivolumab, a monoclonal antibody to PD-1, for treatment of advanced melanoma. Its...

(BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research...

Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma". ClinicalTrials...

include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor...